| http://purl.uniprot.org/citations/14871245 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/14871245 | http://www.w3.org/2000/01/rdf-schema#comment | "Dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the translocation t(4;14)(p16;q32) occurs in 15% of multiple myeloma (MM) patients and confers a growth and survival advantage to malignant plasma cells. As FGFR3 is a molecular target, we assessed the therapeutic potential of the FGFR-specific tyrosine kinase inhibitors SU5402 and SU10991 in MM. SU5402 inhibited FGFR3 phosphorylation in vitro and in murine MM tumour models. B cells dependent on FGFR3 for survival were specifically sensitive to SU5402. A panel of 11 human myeloma cell lines was studied, five bearing the t(4;14) translocation. The KMS11 human myeloma cell line, which expresses constitutively active mutant FGFR3, displayed an 85% decrease in S-phase cells, a 95% increase in G0/G1 cells, and 4.5-fold increase in apoptotic cells after 72 h treatment with 10 micromol/l SU5402. Activated extracellular signal-regulated kinases 1 and 2 and signal transducer and activator of transcription 3 were rapidly down-regulated after SU5402 treatment. In human myeloma cell lines expressing wild-type FGFR3 the stimulating effect of aFGF ligand was abrogated by SU5402 treatment. Myeloma cells lacking the t(4;14) or with the t(4;14) and a secondary RAS mutation did not respond to therapy. These findings support the development of clinical trials of early intervention with FGFR3 inhibitors in t(4;14) myeloma."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.org/dc/terms/identifier | "doi:10.1111/j.1365-2141.2004.04814.x"xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/author | "Chang H."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/author | "Li Z."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/author | "Stewart A.K."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/author | "Wen X.Y."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/author | "Trudel S."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/author | "Masih-Khan E."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/author | "Pollett J.B."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/author | "Paterson J.L."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/date | "2004"xsd:gYear |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/name | "Br J Haematol"xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/pages | "595-603"xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/title | "Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma."xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://purl.uniprot.org/core/volume | "124"xsd:string |
| http://purl.uniprot.org/citations/14871245 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/14871245 |
| http://purl.uniprot.org/citations/14871245 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/14871245 |
| http://purl.uniprot.org/uniprot/#_P09038-mappedCitation-14871245 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14871245 |
| http://purl.uniprot.org/uniprot/#_O76093-mappedCitation-14871245 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14871245 |
| http://purl.uniprot.org/uniprot/#_Q9NP95-mappedCitation-14871245 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14871245 |
| http://purl.uniprot.org/uniprot/#_O43320-mappedCitation-14871245 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14871245 |
| http://purl.uniprot.org/uniprot/#_P55075-mappedCitation-14871245 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14871245 |
| http://purl.uniprot.org/uniprot/#_O60258-mappedCitation-14871245 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14871245 |
| http://purl.uniprot.org/uniprot/#_P08620-mappedCitation-14871245 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14871245 |